WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 3 fonti

Study Finds Some Medical Spas Still Selling Compounded Weight-Loss Drugs From Pharmacies With Regulatory Concerns

Study Finds Some Medical Spas Still Selling Compounded Weight-Loss Drugs From Pharmacies With Regulatory Concerns

Raccontata dabiopharmadive.commorningstar.commedpagetoday.com

Confronto fonti

3 prospettive sulla stessa storia
AI · summaries
morningstar.comStai leggendo5 g fa

Study Finds Some Medical Spas Still Selling Compounded Weight-Loss Drugs From Pharmacies With Regulatory…

Study Finds Some Medical Spas Still Selling Compounded Weight-Loss Drugs From Pharmacies With Regulatory Concerns

originale
medpagetoday.com2 g fa

Troubling Findings in Study of GLP-1 Compounders

Demand for compounded GLP-1 drugs persists despite shortage resolutions

Leggi questa versione → originale

Timeline cronologica

  1. venerdì 17 luglio 2026·biopharmadive.com

    Compounders maintain a firm grip on the GLP-1 market

    Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients taking are still taking cheaper weight-loss alternatives.

  2. venerdì 17 luglio 2026·morningstar.com

    Study Finds Some Medical Spas Still Selling Compounded Weight-Loss Drugs From Pharmacies With Regulatory Concerns

    Study Finds Some Medical Spas Still Selling Compounded Weight-Loss Drugs From Pharmacies With Regulatory Concerns

biopharmadive.com6 g fa

Compounders maintain a firm grip on the GLP-1 market

Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients taking are still taking cheaper weight-loss alternatives.

Leggi questa versione → originale
  • lunedì 20 luglio 2026·medpagetoday.com

    Troubling Findings in Study of GLP-1 Compounders

    Demand for compounded GLP-1 drugs persists despite shortage resolutions